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PRIMARY RESEARCH
AGI-134: a fully synthetic α-Gal glycolipid 
that converts tumors into in situ autologous 
vaccines, induces anti-tumor immunity 
and is synergistic with an anti-PD-1 antibody 
in mouse melanoma models
Stephen M. Shaw1,2, Jenny Middleton1,2, Kim Wigglesworth3, Amber Charlemagne1, Oliver Schulz4, 
Melanie S. Glossop1, Giles F. Whalen3,5, Robert Old6, Mike Westby1, Chris Pickford1, Rinat Tabakman2, 
Irit Carmi‑Levy2, Abi Vainstein2, Ella Sorani2, Arik A. Zur2*  and Sascha A. Kristian1
Abstract 
Background: Treatments that generate T cell‑mediated immunity to a patient’s unique neoantigens are the current 
holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized 
ex vivo processing or manufacturing processes are especially sought after. Here we report that AGI‑134, a glycolipid‑
like small molecule, can be used for coating tumor cells with the xenoantigen Galα1‑3Galβ1‑4GlcNAc (α‑Gal) in situ 
leading to opsonization with pre‑existing natural anti‑α‑Gal antibodies (in short anti‑Gal), which triggers immune 
cascades resulting in T cell mediated anti‑tumor immunity.
Methods: Various immunological effects of coating tumor cells with α‑Gal via AGI‑134 in vitro were measured by 
flow cytometry: (1) opsonization with anti‑Gal and complement, (2) antibody‑dependent cell‑mediated cytotoxicity 
(ADCC) by NK cells, and (3) phagocytosis and antigen cross‑presentation by antigen presenting cells (APCs). A viability 
kit was used to test AGI‑134 mediated complement dependent cytotoxicity (CDC) in cancer cells. The anti‑tumoral 
activity of AGI‑134 alone or in combination with an anti‑programmed death‑1 (anti‑PD‑1) antibody was tested in 
melanoma models in anti‑Gal expressing galactosyltransferase knockout (α1,3GT−/−) mice. CDC and phagocytosis 
data were analyzed by one‑way ANOVA, ADCC results by paired t‑test, distal tumor growth by Mantel–Cox test, C5a 
data by Mann–Whitney test, and single tumor regression by repeated measures analysis.
Results: In vitro, α‑Gal labelling of tumor cells via AGI‑134 incorporation into the cell membrane leads to anti‑Gal 
binding and complement activation. Through the effects of complement and ADCC, tumor cells are lysed and tumor 
antigen uptake by APCs increased. Antigen associated with lysed cells is cross‑presented by CD8α+ dendritic cells 
leading to activation of antigen‑specific CD8+ T cells. In B16‑F10 or JB/RH melanoma models in α1,3GT−/− mice, 
intratumoral AGI‑134 administration leads to primary tumor regression and has a robust abscopal effect, i.e., it pro‑
tects from the development of distal, uninjected lesions. Combinations of AGI‑134 and anti‑PD‑1 antibody shows a 
synergistic benefit in protection from secondary tumor growth.
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Background
Cancer immunotherapy has revolutionized cancer treat-
ment, with therapies that block immune checkpoints 
demonstrating remarkable efficacy in a wide range of 
tumor types [1]. However, there are still a vast number 
of patients who are refractory to these treatments. The 
patients for whom current immunotherapies are not 
efficacious have tumors that have little inflammation 
and T cell infiltration, so-called immunologically cold 
tumors [2]. To boost the efficacy of the immune check-
point inhibitors in refractory patient populations, there 
are several approaches that specifically aim to either: 
(1) produce intratumoral inflammation, (2) increase 
tumor antigen processing and prime naïve T cells against 
tumor-specific antigens (TSAs) or (3) relieve immuno-
suppression in the tumor microenvironment [3, 4].
One method that has been explored to boost tumor tis-
sue processing and produce activation of TSA-specific 
T cells harnesses the ability of pre-existing natural anti-
bodies to mediate rejection of xenogeneic tissue bear-
ing Galα1-3Galβ1-4GlcNAc (α-Gal) epitopes. Humans, 
apes and Old World monkeys do not express the α-1,3-
galactosyltransferase (α1,3GT) enzyme, which catalyzes 
the synthesis of α-Gal epitopes presented on cell sur-
face glycolipids and glycoproteins in other mammals [5]. 
Humans therefore recognize α-Gal epitopes as foreign 
and, through constant antigenic stimulation by commen-
sal gut bacteria expressing α-Gal-like epitopes, produce 
anti-α-Gal antibodies (termed anti-Gal) in titers as high 
as 1% of total immunoglobulin throughout life [6–8]. 
When anti-Gal antibodies bind to α-Gal-bearing tissue, 
they activate the complement cascade and initiate anti-
body-dependent cellular cytotoxicity (ADCC) [9–11], 
resulting in the release of inflammatory mediators and 
lysis of the tissue. It is the activation of complement and 
ADCC by anti-Gal that drives the hyperacute rejection of 
xenotransplants in humans.
The hyperacute response driven by anti-Gal bind-
ing to α-Gal-positive tissue can also stimulate adaptive 
immunity to non-self-antigens within the target tis-
sue [12–16]. Tissue lysis during hyperacute rejection 
produces cellular debris that is immune-complexed 
with anti-Gal IgG and various complement proteins, 
while complement activation will cause the release of 
inflammatory mediators such as the anaphylatoxins 
C3a and C5a, which create an inflammatory tumor 
microenvironment that is optimal for the chemotac-
tic recruitment and activity of antigen presenting cells 
(APCs), such as macrophages and dendritic cells (DCs). 
Immune-complexed antigens are taken up by APCs via 
activating Fcγ (FcγR) and complement (CR) receptors 
and subsequently presented to T cells [17–20]. Accord-
ingly, viral vaccines expressing α-Gal epitopes, which 
form in  situ immune complexes with anti-Gal, are 30- 
to 100-fold more immunogenic than the same vaccines 
lacking α-Gal epitopes [21–23]. Furthermore, tumor 
cell vaccines engineered to express α-Gal are more 
immunogenic than parental tumor cells, while also 
providing greater protection from subsequent parental 
tumor cell challenge [12].
To develop an α-Gal-based immunotherapy, it was 
of interest to determine whether tumor lesions can be 
labeled with α-Gal epitopes in order to convert them 
into in  situ vaccines that elicit a protective immune 
response against autologous TSAs on tumor cells spe-
cific to individual patients by harnessing the natural 
anti-Gal antibody. To that aim, Galili et  al. developed 
an α-Gal glycolipid preparation that was extracted from 
rabbit erythrocytes and could be injected directly into 
cancer lesions [15, 16]. The aim of this intratumoral 
administration of α-Gal glycolipids was to label the 
tumor with α-Gal, which would initiate an immuno-
logical cascade within the tumor that would ultimately 
create lasting immunity to the patient’s own TSAs. 
When cells were treated with the α-Gal glycolipids 
in  vitro, the lipid component spontaneously and sta-
bly is inserted into the cell plasma membranes, pre-
senting α-Gal epitopes for complexation with anti-Gal 
antibodies, which resulted in complement-dependent 
cytotoxicity (CDC) and cell lysis after incubation in 
human serum [15, 16]. When the α-Gal glycolipids 
were administered to primary melanoma lesions in 
anti-Gal producing α-1,3-galactosyltransferase knock-
out (α1,3GT−/−) mice, i.e., mice lacking α-Gal epitopes, 
the mice were protected from the development of sec-
ondary untreated lesions [15, 16]. The anti-tumoral 
effect was demonstrated to be driven by the generation 
of melanoma-associated antigen (MAA)-specific CD8+ 
T cells, which protected the mice from challenge with 
melanoma cells [16]. In two small scale Phase I clinical 
Conclusions: We have identified AGI‑134 as an immunotherapeutic drug candidate, which could be an excellent 
combination partner for anti‑PD‑1 therapy, by facilitating tumor antigen processing and increasing the repertoire of 
tumor‑specific T cells prior to anti‑PD‑1 treatment.
Keywords: Immunotherapy, alpha‑Gal, anti‑Gal, Melanoma, anti‑PD‑1, Checkpoint inhibition, Cancer vaccine, AGI‑
134, Intratumoral injection, Abscopal effect
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trials, the intratumoral administration of these α-Gal 
glycolipids was demonstrated to be well tolerated and 
safe for use in human cancer patients [28, 29].
Due to the impracticality of developing a human thera-
peutic from a crude biological extract, we explored the 
use of a fully synthetic α-Gal glycolipid-like molecule, 
AGI-134, which is a small molecule with a simple, robust 
manufacturing route amenable to full clinical develop-
ment. AGI-134 is a Function-Spacer-Lipid (FSL) mol-
ecule that was originally developed by KODE Biotech 
(Auckland, New Zealand) and is comprised of a lipid 
tail linked to the α-Gal epitope by an adipate linker [30]. 
AGI-134 retains the immunological properties of natu-
rally occurring α-Gal glycolipids extracted from rabbit 
erythrocytes. Here we demonstrate that AGI-134 spon-
taneously incorporates into human and mouse tumor 
cells and binds anti-Gal antibodies, leading to lysis of the 
AGI-134-treated cells through the activation of comple-
ment and ADCC. Complement killed cells were specifi-
cally phagocytosed by human APCs and murine CD8α+ 
dendritic cells, which cross-presented antigen to CD8+ 
T cells. In mouse models of melanoma, intratumoral 
administration of AGI-134 evoked primary tumor remis-
sion and an abscopal effect that protected mice from the 
development of un-injected distant lesions. Finally, we 
present evidence that the anti-tumor efficacy of AGI-
134 is synergistic with an anti-programmed cell death 1 
receptor (PD-1) antibody, suggesting that AGI-134 may 
be an excellent combination partner for synergy with 
checkpoint inhibitor antibodies.
Methods
Test compounds
AGI-134 is an FSL (Function-Spacer-Lipid) molecule 
originally developed by KODE Biotech (Auckland, NZ). 
It is an amphiphilic, water dispersible construct, which 
consists of an α-Gal trisaccharide functional head group, 
a spacer, and a diacyl lipid tail. In addition to AGI-134, 
two other FSL molecules were used in this study: FSL-A 
(functional group: blood group A trisaccharide [31]) and 
FSL-Fluorescein (functional group: fluorescein [32]). 
See Additional file  1: Fig. S1 for the FSL compound 
structures.
Cell lines and primary cells
SW480 human colon adenocarcinoma cells, A549 human 
lung carcinoma and Chinese hamster ovary (CHO-K1) 
cells were purchased from the European Collection of 
Cell Cultures (ECACC). B16-F10 mouse melanoma cells 
were obtained from the American Type Culture Collec-
tion. These cell lines were authenticated at the respec-
tive cell banks via Short Tandem Repeat profiling. JB/
RH mouse melanoma cells were gifted to Dr. Whalen. 
Ovalbumin expressing CHO-K1 (CHO-OVA) cells were 
generated for this study by standard retroviral transduc-
tion techniques. Briefly, retroviral particles were gener-
ated by lipid-based transfection of a host cell line with 
packaging plasmids and a pMSCV expression vector 
encoding a fusion protein consisting of the non-secreta-
ble form of OVA and the red fluorescent reporter pro-
tein mCherry. Retroviral particles were concentrated by 
ultracentrifugation and used to transduce CHO-K1 cells. 
Successful transduction was confirmed by flow cytomet-
ric analysis of transduced CHO-K1 populations, show-
ing the presence of the red fluorescent reporter protein. 
The green fluorescent protein (GFP)-expressing mouse 
tumor dendritic cell (DC) line (MutuDC) was previ-
ously described [33]. DNGR-1 knock out (DNGR-1−/−) 
MutuDCs were generated by CRISPR/Cas9 technology as 
described [34]. OT-I  CD8+ T cells, whose T cell receptors 
recognize the H-2Kb-restricted SIINFEKL OVA peptide, 
were collected as follows: the lymph nodes and spleen of 
one OT-I x recombination activating gene 1 (Rag1) knock 
out mouse were collected and homogenized to obtain a 
single cell suspension. Red blood cells were lysed. The 
residual cells were washed and cultured for 2  days in 
RPMI-1640 supplemented with fetal bovine serum (FBS), 
β-mercaptoethanol, glutamine, penicillin/streptomy-
cin, sodium pyruvate and non-essential amino acids in 
24-well tissue culture plates at 5 × 104–1 × 105 cells/well, 
in the presence of 0.1–1 nM SIINFEKL. Mouse IL-2 was 
added to a final concentration of 250 units/mL on day 3 
and the cultures maintained for another 2 days. On day 5, 
effector CD8+ T cells were enriched from the cultures by 
magnetic activated cell sorting using a negative depletion 
antibody cocktail (Miltenyi Biotec).
Human peripheral blood mononuclear cells (PBMC) 
were prepared from individual donor leukocyte cones 
(obtained from the National Health Service Blood and 
Transplant (NHSBT), United Kingdom) by density gra-
dient centrifugation over Ficoll-Paque Plus (GE Health-
care Lifesciences). NK cells were enriched from freshly 
isolated PBMC using an eBioscience human NK cell 
negative selection kit and cultured overnight in com-
plete NK medium (DMEM supplemented with FBS, 
l-glutamine, sodium pyruvate, non-essential amino 
acids and penicillin/streptomycin) in the presence of 
150 units/mL of recombinant human IL-2 (Peprotech) 
at 37  °C, 5%  CO2. Human PBMC were differentiated 
into macrophages as follows: 2  h after adding PBMCs 
to 6-well plates, adherent cells were washed and dif-
ferentiated by 6- to 7-day incubation in medium with 
100  ng/mL  Macrophage Colony Stimulating Factor 
(M-CSF; Peprotech); Fcγ and complement receptor 
expression was verified by flow cytometry (Additional 
file 2: Fig. S2).
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α‑1,3‑Galactosyltransferase knockout (α1,3GT−/−) mice, 
anti‑Gal induction and titer measurement
Male and female α1,3GT−/− animals with an age 
of up to 8  months and up to 35  g in weight were 
used in this study. The strain was generated on a 
C57BL/6xDBA/2Jx129sv background with  H2b × H2d 
haplotypes [15, 35] and then interbred. To induce anti-
Gal antibody production, the mice received repeated 
intraperitoneal (i.p.) immunizations with pig kidney 
homogenate (PKH) [15, 36]. Anti-Gal titers were deter-
mined as described [37]: 96-well plates were coated 
with bovine serum albumin (BSA)-conjugated to α-Gal 
(α-Gal-BSA; V-Labs) or control BSA. After blocking 
with casein buffer (Thermo Scientific), mouse plasma 
samples diluted in blocking buffer were added. Bound 
antibodies were detected with HRP-conjugated anti-
mouse antibodies, HRP substrate, sulfuric acid stop 
solution, and measuring 492-nm absorbance.
Polyclonal human anti‑Gal IgG purification
Anti-Gal IgG was affinity purified from human serum 
immunoglobulin (Baxter) at Rockland Immunochemi-
cals (Pottstown, PA). α-Gal conjugated to human serum 
albumin (α-Gal-HSA; V-Labs) was immobilized to UF4 
or NHS-activated Sepharose 4 Fast Flow resins (GE 
Healthcare); bound anti-Gal was eluted by low pH, dia-
lyzed 3× in PBS, and sterile-filtered.
Binding of mouse and human anti‑Gal antibodies 
to AGI‑134‑treated mouse and human cancer cells
5 × 105 cancer cells were treated with AGI-134 or con-
trols in phosphate buffered saline (PBS) with rotation 
for 1–2  h at 37  °C. After three PBS washes, FSL-Fluo-
rescein-treated cells could be directly analyzed; AGI-
134- and FSL-A-treated cells were incubated with either: 
α1,3GT−/− mouse or human serum, chimeric anti-Gal 
with human Fc portion (Absolute Antibody, Oxford, UK), 
affinity purified human anti-Gal, or anti-blood Group 
A,B antibody in PBS, 0.1% BSA or RPMI-1640 and then 
with fluorescein isothiocyanate (FITC)-labeled second-
ary antibodies (Biolegend and Sigma) prior to analysis by 
flow cytometry or fluorescence microscopy. To visualize 
cell nuclei in the microscopy samples, the test samples 
were stained with 4′,6-diamidino-2-phenylindole (DAPI; 
Abcam). Fluorescence pictures were taken using a dual 
band filter set allowing for simultaneous visualization of 
DAPI and FITC fluorescence.
Complement deposition and complement‑dependent 
cytotoxicity (CDC) experiments
For complement deposition assays, AGI-134- or FSL-
A-treated cells were incubated with 2.5–50% pooled 
normal human serum (NHS; Innovative Research) or 
α1,3GT−/− mouse serum for 10–45 min at 37 °C (modi-
fied from 62). Then, the cells were washed three times 
with cell staining buffer (CSB, Biolegend) and then 
incubated with anti-C3b/C3bi (Thermo Scientific) or 
anti-C5b-9 membrane attack complex (MAC; Quidel) 
antibodies in CSB for 30 min on ice, then washed 3×, 
incubated with FITC- or allophycocyanin-conjugated 
secondary antibodies for 30 min on ice, washed again, 
and subjected to flow cytometry.
For CDC assays, 5 × 105 human SW480 or A549 cells 
were treated with AGI-134 or vehicle for 2  h at 37  °C 
with rotation. After three PBS washes, 1 × 105 cells were 
added to white 96-well plates in RPMI-1640 and incu-
bated with a final concentration of 50% NHS or heat-
inactivated NHS (iNHS; NHS was treated for 30  min 
at 56  °C to obtain iNHS). To verify MAC-contribution 
to complement-mediated killing, some experiments 
with SW480 cells were conducted with C7-depleted 
human serum ± physiological C7 amounts (70  μg/mL; 
both Quidel). The plates were incubated for 1–2  h at 
37 °C, 5%  CO2. To measure cell viability, the CellTiter-
Glo Luminescent Cell Viability Assay (Promega), which 
measures ATP as viability indicator, was used. For NHS 
vs. iNHS dose response assays, the average lumines-
cence of untreated cells was set as 100% viability. For 
experiments with C7-depleted serum ± C7, the mean 
luminescence of cells incubated with C7-depleted 
serum was set as 100%.
Antibody‑dependent cell‑mediated cytotoxicity (ADCC) 
reporter assay experiments
An ADCC Reporter Bioassay Core Kit (Promega) was 
used according to the manufacturer’s instructions. 
Briefly, A549 cells were rotated in PBS ± 0.5  mg/ml 
AGI-134 for 1  h at 37  °C. Cells were then washed 3× 
in ice-cold PBS and then added to 96-well assay plates 
at 3 × 103 viable cells/mL in kit assay buffer. Effector 
and target cells were incubated at a 10:1 ratio in assay 
buffer containing 0 or 30 µg/mL affinity purified human 
anti-Gal IgG. After a 6-h incubation at 37 °C, 5%  CO2, 
Bio-Glo luciferase reagent was added to each well and 
relative light units (RLU) measured using a biolumines-
cence plate reader. Blank RLU values were obtained by 
averaging the RLU values obtained for wells containing 
assay buffer and Bio-Glo luciferase reagent only. Fold-
ADCC induction was calculated as [RLU in the pres-
ence of anti-Gal − Blank RLU]/[RLU in the absence of 
anti-Gal − Blank RLU]. Within each assay run, fold-
ADCC induction in the presence of AGI-134 was nor-
malized against fold-ADCC induction in the absence of 
AGI-134.
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Primary NK cell‑mediated ADCC cell killing experiments
CHO-K1 target cells were stained with 1.25  µM of the 
green fluorescent dye carboxyfluorescein succinimi-
dyl ester (CFSE) and cultured overnight in F12-Ham 
medium supplemented with FBS and l-glutamine at 
37 °C, 5%  CO2. Then, the cells were harvested and rotated 
in the dark in PBS ± 1 mg/mL AGI-134 for 1 h at 37 °C. 
After three washes with ice-cold PBS, the target cells 
were added to a round-bottom 96-well plate at 2–3 × 104 
viable cells per well and incubated with or without 
20–30  µg/mL affinity purified human anti-Gal IgG for 
45 min at 4 °C in the dark. Human NK effector cells were 
isolated and incubated in IL-2 as described above. NK 
effector and CFSE-labeled target cells were co-incubated 
at a ratio of 8:1 for 4 h at 37 °C, 5%  CO2 in the dark. Then, 
the viability dye 7-Aminoactinomycin D (7-AAD; Bioleg-
end) was added to each sample and incubated for at least 
5 min at 4 °C in the dark before flow cytometric analysis. 
CFSE-positive target cells populations were identified in 
forward scatter (FSC) vs. FL-1 dot blots. The percentage 
of dead cells in the target cell population was determined 
as the percentage of CFSE+ 7-AAD+ cells. Percentage 
ADCC was calculated as the percentage cell death in the 
presence of anti-Gal IgG minus the percentage cell death 
in the absence of anti-Gal IgG.
Human macrophage phagocytosis experiments
Human monocyte-derived macrophages (MDMs) were 
prepared as described above, then intracellularly stained 
with 200  nM Far Red CellTrace (Life Technologies) in 
PBS for 20 min at 37 °C, washed, and incubated overnight 
in culture medium + 100  ng/mL  M-CSF. A549 target 
cells were labeled with 1.25 μM CFSE in PBS, 0.1% BSA 
for 10 min, washed with PBS, and incubated overnight at 
37 °C, 5%  CO2. 2.5 × 106 CFSE-labeled A549 cells/mL in 
RPMI-1640 were incubated with 0–500 μg/mL AGI-134 
for 2  h at 37  °C with rotation. After three PBS washes, 
the cells were incubated for 45  min at 5 × 106 cells/mL 
in RPMI-1640 (no serum control) or RPMI-1640, 50% 
NHS as anti-Gal and complement source. Subsequently, 
the cells were washed and quantified. 3 × 105 opsonized 
A549 cells were then added to 1 × 105 macrophages in 
200 μL culture medium. The samples were incubated at 
37  °C for 2 h. For analysis, the cell mixture was washed 
once and the macrophages stained with PE/Dazzle 
594-labeled anti-CD11b antibody (Biolegend) and then 
washed. In experiments to demonstrate internaliza-
tion of A549 cells by macrophages, 5 μM cytochalasin D 
(Sigma-Aldrich) was used as phagocytosis inhibitor [38] 
and 0.25% trypsin–EDTA (Sigma-Aldrich) was used to 
detach adherent A549 cells from macrophages. In these 
experiments, the MDMs were intracellularly stained with 
200 nM Far Red CellTrace (Life Technologies) in PBS for 
20 min at 37 °C, washed, and incubated overnight in cul-
ture medium + 100 ng/mL M-CSF. After co-incubation of 
Far Red-labeled macrophages with CFSE-labeled A549 
cells, as described above, 0.25% trypsin–EDTA was used 
to separate macrophages that had adhered to, rather than 
internalized, A549 cells. All samples were analyzed by 
flow cytometry. CD11b-positive cells (macrophages) that 
were also CFSE-positive were defined as macrophages 
with cell-associated (adherent or phagocytosed) A549 
target cells. In samples in which trypsin/EDTA was used, 
FarRed+ cells (macrophages) that were also CFSE+ were 
defined as macrophages with phagocytosed target cells. 
Cytochalasin D-treated samples served as controls to 
show inhibition of phagocytosis.
Dendritic cell phagocytosis and in vitro cross‑presentation 
experiments
CHO-K1 target cells were incubated for 1  h in PBS, 
500  µg/mL AGI-134 at 37  °C. After washing, the cells 
were incubated with 50% pooled NHS at 37 °C for 1 h to 
induce serum-mediated killing of the AGI-134-treated 
cells. Cell death was confirmed by staining with the 
viability dye DAPI. After one PBS wash, the cells were 
labeled with the red fluorescent dye CellVue Claret 
(Sigma-Aldrich) per the manufacturer’s instructions. 
The degree of Claret dye incorporation for each target 
cell treatment group (AGI-134+ serum or serum alone) 
was determined by measuring the geometric mean fluo-
rescence intensity (gMFI) for the Claret dye channel for 
each treatment group. These values were used to normal-
ize the DC uptake data as detailed below. Stained target 
cells were co-cultured with MutuDC effector cells at a 1:1 
ratio for 30–120 min at 37 °C, 5%  CO2 and then analyzed 
by flow cytometry. Viable MutuDCs were identified as 
GFP+ DAPI-cells and the level of target cell uptake was 
determined as the degree of transfer of Claret signal to 
the MutuDC population. To account for any differences 
in the degree of initial Claret dye incorporation into the 
target cell treatment groups, Claret signal in the MutuDC 
populations following co-culture with target cells was 
normalized by calculating [MutuDC geo. MFI ×  (A:B)], 
where: A = lowest Claret gMFI of the two target cell 
treatment groups, B = Claret gMFI of the target cell treat-
ment group co-cultured with the MutuDCs.
Cross-presentation experiments were conducted as 
described [34]. CHO-OVA target cells were treated with 
PBS, 500  µg/mL of AGI-134 at 37  °C for 1  h and then 
washed with refrigerated PBS. The cells were then incu-
bated with 50% pooled NHS at 37  °C for 1  h to induce 
complement-mediated killing of the AGI-134-labeled 
cells. An aliquot of the target cells was stained with DAPI 
and the dead cells were quantified using liquid count-
ing beads (Becton–Dickinson) by flow cytometry. Dead 
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cells were added to 96-well U-bottom plates in duplicate, 
in complete medium (RPMI-1640 supplemented with 
FBS, beta-mercaptoethanol, l-glutamine, sodium pyru-
vate, non-essential amino acids, HEPES, and penicillin/
streptomycin), in a 3-fold dilution series. Wild-type and 
DNGR-1 knock out (KO) MutuDC were harvested from 
tissue culture dishes, counted and resuspended in com-
plete RPMI medium. MutuDCs were added to the target 
cells in the 96-well assay plates at varying concentra-
tions, giving a final dead cell:MutuDC ratios of 3:1 to 1:9. 
MutuDC and dead target cells were co-cultured for 4  h 
at 37  °C, 5%  CO2. For the soluble OVA protein control, 
MutuDC were co-cultured with soluble OVA protein 
instead of dead cells. After 4 h incubation, pre-activated 
OT-I  CD8+ T cells, prepared as described above, were 
added to each well in complete RPMI medium at an OT-
1:MutuDC ratio of 3:1 and incubated overnight at 37 °C, 
5%  CO2. IFN-γ concentrations in sample supernatants 
were determined by ELISA.
Mouse melanoma models and measurement 
of complement activation in B16‑F10 tumors
For single tumor regression experiments, the right flank 
of α1,3GT−/− mice was shaved and 2.5 × 105 B16-F10 
cells administered into the flank by subcutaneous (s.c.) 
injection on Day 0. When the tumors reached ~ 2–4 mm 
in diameter they were treated twice with a 1.25 mg dose 
of AGI-134 delivered intratumorally (i.t.) in 50 µl of PBS, 
each dose administered 24  h apart. Control mice were 
treated intratumorally with 2 × 50 µl of PBS alone. After 
treatment, the tumor volume was monitored for the dura-
tion of the study. In abscopal effect studies, both flanks of 
α1,3GT−/− mice were shaved and, on Day 0, 1 × 106 B16-
F10 cells or 5 × 105 JB/RH cells in PBS were s.c. injected 
into the right flank, and 1 × 104 B16-F10 cells or 2 × 104 
JB/RH cells injected s.c. into the contralateral flank. The 
resulting tumors were designated as primary (1°) and 
secondary (2°) tumors, respectively. When the 1° tumors 
reached ~ 5  mm in diameter (Day 4–5 post-grafting), 
they were treated with a single i.t. dose of AGI-134 in 
100 µL PBS, or mock treated with PBS only. In combina-
tion experiments with anti-PD-1, 1° tumors were treated 
i.t. with PBS or AGI-134 as above. On Days 5, 8, or 10, 
the mice received the first intraperitoneal (i.p.) dose of 
250  μg anti-PD-1 antibody RMP1-14 (BioXcell; [39]) in 
200 µL PBS. The anti-PD-1 treatment was repeated ×3 
in 3–4-day intervals. Tumor sizes were determined with 
calipers or Image J software [40]; tumor volumes were 
calculated by the modified ellipsoidal formula: Tumor 
volume  (mm3) = Length [mm] × Width [mm] × Width 
[mm] × 0.5 [41, 42]. Mice with tumors exceeding 20 mm 
in diameter were euthanized according to Institutional 
Animal Care and Use Committee (IACUC) guidelines. 
To enable observation periods for up to 90  days with-
out having to euthanize mice, 1° tumors with 10–15 mm 
diameter were ablated by i.t. treatment with 150 μL abso-
lute ethanol (Sigma-Aldrich). The presence or absence of 
visible and/or palpable 2° tumors was assessed 2–3 times/
week.
To examine complement activation after intratumoral 
injection of AGI-134 or PBS, B16-F10 tumors were 
induced on the right flanks of α1,3GT−/− mice using 
1 × 106 cells. Between Day 5–11, the tumors were treated 
once i.t. with 1 mg AGI-134 in 100 μL PBS or PBS alone. 
After 2–2.5 h, the tumors were excised and placed in PBS 
with protease inhibitor cocktail to prevent further com-
plement activation or degradation. C5a was measured in 
tumor homogenate supernatants by ELISA (Abcam).
Histology
B16-F10 tumors were induced on the right flank and left 
flanks of α1,3GT−/− mice by s.c. injecting 1 × 106 mela-
noma cells. On Day 6, the tumors on the right flanks 
were treated with 100 µg FSL-Fluorescein in 100 μL PBS. 
As a control, the tumors on the left flanks were mock 
treated with 100 µL PBS. The following day, the tumors 
were excised and frozen in OCT compound (Tissue Tek). 
Tumor sections were labeled with DAPI and microscope 
images in the GFP (to visualize FSL-Fluorescein) and 
DAPI (for DNA of cell nuclei) channels were taken and 
electronically overlaid.
Statistical analyses
CDC and phagocytosis data were compared by one-way 
ANOVA. ADCC experiments were analyzed by paired 
t-test. Single tumor regression studies were analyzed by 
repeated measures analysis and back transformed least 
square geometric means were calculated for fold-change 
analysis (SAS JMP Pro 13). Secondary tumor and ethanol 
treatment data were analyzed using the Mantel-Cox test. 
C5a complement ELISA data were assessed by Mann–
Whitney test. For all statistical tests, p values < 0.05 were 
considered statistically significant.
Results
Human anti‑Gal antibodies bind to AGI‑134‑treated human 
cancer cells
To initiate the immunological cascade that ultimately 
results in antitumor immunity, AGI-134 must first incor-
porate into tumor cell plasma membranes and present 
the α-Gal antigen for binding by anti-Gal antibodies. 
When SW480 and A549 human cancer cells were treated 
with different concentrations of AGI-134, there was a 
concentration-dependent increase in the binding of affin-
ity purified human anti-Gal IgG antibodies to the cells, 
as determined by flow cytometry (Fig.  1a). Anti-Gal in 
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human serum also bound to AGI-134-treated cells, as 
when AGI-134-treated A549 cells were incubated with 
heat-inactivated normal human serum (iNHS), binding 
of IgG and IgM antibodies was observed (Fig.  1a). Fur-
thermore, immunofluorescence experiments demon-
strated that AGI-134 and anti-Gal interact on the surface 
of A549 cells, which is consistent with incorporation of 
AGI-134 into the cancer cell membranes (Additional 
file 3: Fig. S3A).
Anti‑Gal binding to AGI‑134‑treated cells activates 
complement and antibody‑dependent cellular cytotoxicity 
(ADCC)
Having demonstrated that AGI-134-treated cells are 
opsonized by anti-Gal IgG and IgM, we next explored 
the effector functions elicited by these antibodies. IgM 
antibodies are potent activators of the classical comple-
ment pathway, while IgG antibodies can activate an array 
of effector functions that include complement deposition 
and FcγRIIIa-dependent ADCC by NK cells.
To investigate if AGI-134-mediated anti-Gal bind-
ing results in activation of complement, A549 cells were 
treated with AGI-134, then incubated in normal human 
serum (NHS) as complement and anti-Gal source before 
complement deposition was analyzed by flow cytom-
etry. As anticipated, AGI-134 induced the deposition of 
complement C3b/C3bi and led to the formation of the 
membrane attack complex (MAC) C5b-C9 on A549 can-
cer cells (Additional file 3: Fig. S3B). Consistent with the 
deposition of MAC molecules, AGI-134-treated SW480 
and A549 cells were killed by NHS in an AGI-134 con-
centration-dependent manner (Fig.  1b). The killing of 
the SW480 cancer cells was complement dependent, 
since the cells were not killed by human serum that 
was depleted of complement activity through heat-
inactivation or removal of C7, a critical component of 
the MAC (Fig.  1b). When the C7-depleted serum was 
supplemented with a physiological concentration of 
human C7 (70 μg/ml), serum killing activity in the pres-
ence of AGI-134 was restored (Fig.  1b). Interestingly, 
the latter cell line was more resistant to CDC which 
may be due to higher expression of complement regula-
tory proteins such as CD55 and CD59 (Additional file 3: 
Fig. S3D). Another indicator of complement activation 
is the generation of the chemotactic anaphylatoxin C5a. 
When the assay supernatants were assayed for the pres-
ence of C5a, significantly increased C5a concentrations 
were observed in samples treated with AGI-134 and NHS 
compared to samples treated with AGI-134 and iNHS or 
NHS or iNHS only (data not shown).
ADCC was assessed using two separate methods: 
an ADCC reporter assay that measured IgG-induced 
FcγRIIIa activation on an ADCC reporter cell line and a 
second assay measuring primary human NK cell-medi-
ated ADCC. When AGI-134-treated A549 cells were 
incubated with affinity purified human anti-Gal IgG and 
co-cultured with ADCC reporter assay effector cells, 
there was a two-fold increase in the amount of FcγRIIIa 
activation in AGI-134-treated samples compared to con-
trol samples that were treated with anti-Gal only (Fig. 1c; 
left graph). In experiments performed using primary 
blood NK cells enriched from several different donors 
(NK cells from a different donor were used in each inde-
pendent experiment), AGI-134 treatment reproduc-
ibly induced NK-cell mediated ADCC of CHO-K1 cells 
(Fig. 1c; right graph).
AGI‑134‑treated cells are phagocytosed by antigen 
presenting cells (APCs)
To initiate adaptive antitumor immune responses, the 
cancer cells and cellular debris created by AGI-134-in-
duced CDC and ADCC, which is complexed with anti-
Gal and complement, must be internalized and processed 
by APCs before TSAs can be presented to T cells.
Fig. 1 Anti‑Gal binds to AGI‑134‑treated human cancer cells and activates CDC and ADCC. a Human SW480 and A549 cancer cells were treated 
with PBS (open histograms) or the indicated concentrations of AGI‑134 (grey and black histograms). The cells were then incubated with affinity 
purified human anti‑Gal IgG or 25% heat‑inactivated human serum. Anti‑Gal antibody binding was detected with fluorescently‑labeled secondary 
antibodies and samples analyzed by flow cytometry. Representative histogram overlays from two to three independently conducted experiments 
for each data set are shown. b SW480 and A549 cells were treated with half‑log dilutions of AGI‑134 and incubated with 50% normal (NHS) or 
heat‑inactivated (iNHS) human serum. In some experiments, SW480 cells were exposed to C7 depleted serum ± 70 µg/mL C7. Cell viability was 
determined using a luminescence‑based cell viability assay and data normalized and expressed as percentage viability. Representative data from 3 
independent experiments are shown, with mean values ± SD. c A549 cells were treated with PBS or 0.5 mg/mL AGI‑134 and then co‑cultured with 
Promega’s ADCC reporter bioassay effector cells in a 25:1 effector:target cell ratio, in the presence or absence of 30 µg/mL affinity purified human 
anti‑Gal IgG for 6 h. Induction of ADCC over no anti‑Gal antibody controls was determined by addition of Bio‑Glo Luciferase reagent to quantify 
reporter gene expression downstream of FcγRIIIa. For assessment of target cell killing by NK cells, CHO‑K1 cells were treated with PBS or 1 mg/mL 
AGI‑134 and pre‑incubated with 30 µg/mL affinity purified human anti‑Gal IgG, before co‑culture with IL‑2‑activated human NK cells. After 4–6 h of 
co‑culture the percentage of dead CHO‑K1 cells was determined by incorporation of the viability dye 7‑AAD into the target cells. Data shown is the 
mean + SEM for three (reporter bioassay) or six (cell killing assay) independent experiments
(See figure on next page.)
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First, we studied the ability of human monocyte-
derived macrophages (MDMs) to phagocytose human 
cancer cells that had been treated with AGI-134 and 
NHS. In these experiments, the A549 cells were treated 
with a concentration of AGI-134 (500 μg/ml) that did not 
induce cell killing by NHS, with the consequence that the 
AGI-134-treated A549 cells were viable, but opsonized 
with anti-Gal antibodies and complement (data not 
shown). When AGI-134- and NHS-treated cells were 
co-cultured with human MDMs, there was an approxi-
mately two-fold increase in the number of phagocytic 
events when compared to controls, as determined by 
flow cytometry (Fig. 2a). Control experiments were per-
formed using trypsin/EDTA and the endocytosis inhibi-
tor cytochalasin D to demonstrate that the data obtained 
was due to phagocytosis, and not cell–cell interactions, 
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b AGI-134- and human serum-treated cells are phagocytosed by dendric cells 
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Fig. 2 AGI‑134‑treated cells are phagocytosed by antigen‑presenting cells and antigen cross‑presented. a CFSE‑labeled A549 cells were 
treated with PBS or 500 μg/mL AGI‑134 and then incubated with or without normal human serum (NHS) to opsonize them with anti‑Gal and 
complement. Subsequently, human macrophages were added at a A549 to macrophage ratio of 3:1. Subsequently, the co‑cultures were stained 
with an anti‑CD11 antibody and analyzed by flow cytometry. CFSE (for A549 cells) vs. CD11b (for macrophages) dot plots are shown for the 
various conditions. Double‑positive events were assumed to be macrophages with associated (adherent or phagocytosed) A549 cells. In the bar 
graphs, the results of three independent experiments, specifically the average percentages of double positive events + SD are shown (*p < 0.05; 
**p < 0.005; ns, not significant; one‑way ANOVA). b CHO‑K1 cells were treated with 1 mg/ml AGI‑134 and then with or without 50% NHS. Cell 
killing was determined by DAPI‑staining of a cell aliquot. The range gates in the histogram plots quantified dead cells. The remaining CHO‑K1 cells 
were stained with CellVue Claret dye and incubated with GFP‑expressing MutuDC cells at 1:1 ratios. Samples were removed from the co‑culture 
after 30–120 min, and analyzed by flow cytometry. The CellVue Claret dye geometric mean fluorescence intensities (gMFIs) were normalized as 
described in the methods and then plotted against time. c CHO‑K1 cells were transduced to express OVA tagged with the fluorophore mCherry. 
The histogram shows an overlay for the mCherry signal for CHO‑K1 parental cells (open curve) and CHO‑OVA cells (closed curve). After treatment 
with vehicle or 1 mg/ml AGI‑134, the CHO‑OVA cells were incubated with 50% NHS before co‑culture with wild‑type or DNGR‑1 KO MutuDCs at the 
indicated range of dead CHO‑OVA:MutuDC cell ratios. After 4 h, OT‑1 CD8+ T cells were added to the co‑culture and incubated overnight. OT‑1 T 
cell activation was quantified by IFN‑γ ELISA of the co‑culture supernatants
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i.e., adherence of target to effector cells (Additional file 3: 
Fig. S3C).
To activate naïve antigen-specific CD8+ T cells, 
dendritic cells (DCs) cross-present MHC I-restricted 
antigen. In particular, the CD141+/XCR1+ subset in 
humans, and their murine CD8α+/XCR1+ counterparts, 
are key subsets of DCs involved in cross-presentation 
[43]. We therefore tested whether, like human MDMs, 
murine CD8α+ DCs (MutuDCs) are able to specifically 
phagocytose AGI-134- and NHS-treated cells. Since 
CHO-K1 cells are almost 100% killed by human serum 
after AGI-134 treatment, they were selected as the target 
cells. First, CHO-K1 cells were treated ± AGI-134 (1 mg/
ml), incubated with NHS and cell viability determined 
by flow cytometry (Fig. 2b). Cells treated with both AGI-
134 and NHS were almost 100% killed by human serum, 
whereas those treated with NHS alone were > 75% viable. 
After NHS treatment, the cells were loaded with the red 
fluorescent dye CellVue Claret and co-cultured with 
GFP+ MutuDCs. Phagocytosis was measured as trans-
fer of Claret signal to the MutuDC cell population over 
time (Fig.  2b). There was a time-dependent increase in 
the transfer of Claret signal to the MutuDCs from cells 
that had been killed through treatment with AGI-134 and 
NHS, but not those live cells that had been treated with 
serum alone, suggesting that the killed target cells were 
phagocytosed by the DCs.
Antigen from AGI‑134‑treated cells is cross‑presented 
by CD8α+ DCs
Having demonstrated that MutuDCs are capable of 
phagocytosing CHO-K1 cells killed by AGI-134 and 
NHS treatment, we assessed whether antigen associated 
with the dead CHO-K1 cells is cross-presented. We first 
transduced CHO-K1 cells to express the model neoan-
tigen ovalbumin (OVA) conjugated to the fluorescence 
marker mCherry (Fig.  2c). The mCherry-OVA CHO-
K1 cells were treated with AGI-134 and NHS to induce 
CDC; the dead cells were quantified and co-incubated 
with wild-type or DNGR-1−/− MutuDCs at dead CHO-
K1:MutuDC ratios ranging from 3:1 to 1:9. After incu-
bation, purified OT-1 CD8+ T cells, with transgenic T 
cell receptors that specifically recognize SIINFEKL (the 
immunodominant antigen of OVA) [44], were added to 
the co-culture. After overnight incubation, OT-1 cell acti-
vation was measured by IFN-γ ELISA. We observed that 
OT-1 cell activation was directly proportional to the dead 
CHO-K1 to MutuDC ratio (Fig.  2c). When the experi-
ment was performed in parallel using DNGR-1−/− KO 
MutuDCs, there was no OT-1 T cell activation. DNGR-1 
is a danger associated molecular pattern (DAMP) sens-
ing receptor on DCs that recognizes the DAMP F-actin, 
an event that has been demonstrated to be critical for 
DCs to sense dead cells [45]. DNGR-1−/− MutuDCs are 
still able to cross-present soluble antigen, as incubation 
of soluble OVA with MutuDCs prior to co-culture with 
OT-1 cells resulted in OT-1 cell activation that was equal 
to wild-type cells (data not shown).
AGI‑134 binds serum anti‑Gal antibodies and activates 
complement on treated murine cells
After demonstrating that AGI-134 treatment of cells 
in  vitro initiates an immunological cascade that ulti-
mately results in the activation of CD8+ T cells against 
cell-associated antigens, we evaluated the antitumor 
efficacy of AGI-134 in abscopal models of murine 
melanoma.
Importantly, wild-type mice and most mouse cell 
lines express α-Gal epitopes and thus cannot be used 
to test α-Gal-based immunotherapies. In contrast, 
α1,3GT−/− mice [15, 35], like humans, do not possess 
a functional α1,3GT gene and therefore do not express 
α-Gal epitopes. Consequently, α1,3GT−/− mice pro-
duce anti-Gal IgM and IgG antibodies in titers similar 
to those seen in humans in response to immunization 
with α-Gal-positive tissue [14, 35, 36, 46]. AGI-134 
activity was tested in B16-F10 and JB/RH melanoma 
models in the α1,3GT−/− mice, since these cell lines 
have been demonstrated to be among the few mouse 
cancer cells lines that do not express α-Gal [47].
We first established, as with human cancer cells, that 
AGI-134 incorporates into the plasma membranes of 
mouse B16-F10 and JB/RH cells by demonstrating the 
binding of monoclonal mouse anti-Gal IgM antibody 
to AGI-134-treated cells in vitro (Additional file 4: Fig. 
S4A). Next, binding of IgG and IgM antibodies from 
anti-Gal expressing α1,3GT−/− mouse plasma to AGI-
134-treated B16-F10 cells was demonstrated. Specifi-
cally, the cells were treated with or without AGI-134 
(500  μg/ml) and then incubated with plasma from 
PKH-immunized (highly anti-Gal-positive) or, as a con-
trol, non-immunized (low anti-Gal titers) α1,3GT−/− 
mice (see Additional file 5: Fig. S5A for representative 
anti-Gal titers in non-immunized and PKH-treated 
α1,3GT−/− mice). Plasma anti-Gal binding to the 
treated cells was detected with a secondary antibody 
against both mouse IgG and IgM and the cells analyzed 
by flow cytometry. There was a strong increase in bind-
ing of plasma antibodies to B16-F10 cells treated with 
AGI-134 and incubated with anti-Gal-positive plasma, 
compared to untreated cells or those incubated with 
anti-Gal-negative plasma (Additional file  4: Fig. S4B). 
This data indicates that AGI-134 selectively binds anti-
Gal antibodies from α1,3GT−/− mouse plasma to the 
B16-F10 cells.
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To demonstrate a functional consequence of anti-
Gal binding to AGI-134 treated melanoma cells in this 
murine system, we incubated AGI-134-treated B16-
F10 cells with anti-Gal-positive or negative α1,3GT−/− 
mouse serum and examined complement deposition by 
flow cytometry. While C3b and MAC complement pro-
teins were deposited on the cells from anti-Gal positive 
mouse serum, considerably less was deposited from 
anti-Gal negative serum (Additional file  4: Fig. S4C). 
Furthermore, when cells were treated with FSL-A, an 
analogue of AGI-134 in which the functional α-Gal 
group is replaced with blood group A antigen, no depo-
sition of complement from either anti-Gal-positive or 
negative mouse serum was observed, further demon-
strating the specificity of AGI-134 in mediating bind-
ing of anti-Gal antibodies to B16-F10 cells (Additional 
file 4: Fig. S4D).
Intratumoral administration of AGI‑134 into primary 
lesions causes tumor regression and protects mice 
from the development of secondary lesions
Having demonstrated that AGI-134 has a functional 
effect in murine in  vitro systems as well as human, we 
next tested the efficacy of AGI-134 in models of murine 
melanoma in anti-Gal expressing α1,3GT−/− mice.
First, to examine the tumor distribution of AGI-134 
after intratumoral administration, an analogue of AGI-
134 in which the functional α-Gal group was replaced 
with fluorescein (FSL-Fluorescein) was used to allow 
microscopic analysis. When primary tumors were 
injected with FSL-Fluorescein and resected 24  h later, 
strong fluorescence staining of the tumor sections was 
observed, indicating that the glycolipid had distributed 
throughout the tumor and was still present 24 h later 
(Fig. 3a).
Having demonstrated that AGI-134 induces comple-
ment activation in  vitro, we next determined if intratu-
moral administration of AGI-134 activated complement 
within injected B16-F10 tumors. Consistent with the 
in  vitro findings, AGI-134 evoked intratumoral comple-
ment activation that resulted in significantly raised lev-
els of C5a compared to tumors treated with vehicle alone 
(Fig. 3b).
To then test the ability of AGI-134 to induce regression 
of established tumors, a subcutaneous single flank B16-
F10 tumor model in α1,3GT−/− mice was used. Once the 
lesion had reached an injectable size (~ 2–4 mm in diam-
eter) it was treated intratumorally with either AGI-134 or 
PBS and the tumor volume monitored for up to 32 days 
post B16-F10 cell grafting. Two intratumoral 1.25-mg 
doses of AGI-134, delivered 24  h apart, resulted in sig-
nificant regression of the tumor when compared to mice 
treated with PBS alone (Fig. 3c).
To examine the abscopal efficacy of AGI-134, 
α1,3GT−/− mice were implanted with B16-F10 tumor 
cells to produce single primary and secondary lesions 
on each flank (see Fig. 4a for a schematic representation 
of the B16-F10 model). After the primary lesions had 
reached a diameter of ~ 5 mm, they were injected with a 
single dose of the test compound and growth of the con-
tralateral tumor monitored for the duration of the study.
In mice bearing tumors on both flanks, a single injec-
tion of AGI-134 into primary tumors conferred sig-
nificant protection from the development of uninjected 
tumors on the contralateral flank in four independent 
experiments (Table  1). When the data from the four 
experiments were summarized, contralateral tumors 
developed in 86% (31/36) of PBS-treated mice within the 
25-day observation period, whereas they developed in 
only 16% (6/37) of AGI-134-treated mice (Fig.  4b). The 
efficacy of AGI-134 was dose-dependent, with a maximal 
abscopal effect observed with a 1-mg dose and reduced 
efficacy with doses of 0.5 and 0.1 mg, which were still sig-
nificant when compared to mock-treated controls (Addi-
tional file 5: Fig. S5B).
The abscopal effect of AGI-134 was completely depend-
ent on the expression of anti-Gal antibodies. AGI-134 did 
not protect mice from distal tumor development that 
were non-immunized, and thus anti-Gal negative, but it 
did protect those that were expressing anti-Gal (Fig. 4c), 
demonstrating that the abscopal effect induced by AGI-
134 in the B16-F10 model was dependent on the interac-
tion of anti-Gal with the α-Gal portion of AGI-134.
To test the durability of AGI-134 efficacy, two longer-
term experiments lasting 60 or 90 days were performed, 
which demonstrated that a single 1-mg intratumoral dose 
of AGI-134 protected mice from the development of con-
tralateral tumors for > 60 (Fig. 4d) and > 90 days (data not 
shown).
It must be noted that grafting of 1 × 106 B16-F10 cells 
creates a rapidly growing primary tumor. As AGI-134 
is administered only once, and to enable longer obser-
vation periods studying the development of secondary 
tumors while not violating IACUC approval, which states 
that mice with tumors over 20 mm in diameter must be 
euthanized, the primary tumors were ablated by intratu-
moral injection with ethanol if they reached a diameter 
of 10  mm. Importantly, there was no significant differ-
ence in the timing or requirement for ethanol ablation 
of primary tumors in the PBS- or AGI-134-treated mice 
(29/36 PBS and 24/37 AGI-134 mice required ethanol 
ablation; p < 0.18; Mantel-Cox test, data not shown). As 
AGI-134 clearly protected mice from the development of 
contralateral tumors, we can conclude that ethanol abla-
tion of the primary tumors did not influence the efficacy 
of AGI-134.
Page 12 of 19Shaw et al. Cancer Cell Int          (2019) 19:346 
The data on the abscopal effects of AGI-134 injected 
into the primary lesion were further validated in an addi-
tional model of mouse melanoma. As with B16-F10 cells, 
JB/RH mouse melanoma cells lack α-Gal expression [47] 
and thus provide an additional model in which it is fea-
sible to investigate the anti-tumor activity of AGI-134 
in α1,3GT−/− mice. In the JB/RH model, a single dose 
of AGI-134 injected into a primary tumor significantly 
protected mice from the development of contralateral 
tumors, as well as providing a significant survival benefit 
(Fig. 5).
AGI‑134 boosts the antitumor efficacy of anti‑PD‑1 
antibodies in a B16 melanoma model
Previous studies demonstrated that the abscopal anti-
tumor effect conferred by intratumoral administration 
of rabbit erythrocyte-derived α-Gal glycolipids involved 
the activation of tumor-antigen specific CD8+ T cells 
[16]. We have demonstrated here that SIINFEKL is 
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Fig. 3 Primary tumor treatment with AGI‑134 causes tumor regression, activates complement and FSL distribution in tumors. a Glycolipid 
detection in B16‑F10 tumors: FSL‑Fluorescein was used as surrogate molecule for AGI‑134 visualization in tumors. 1 × 106 B16‑F10 cells were 
grafted onto immunized α1,3GT−/− mice on both flanks. Five days later, the two tumors on each mouse were treated with 100 μL of 1 mg/mL 
FSL‑fluorescein on one flank and with 100 μL PBS on the other flank. The following day, the tumors were excised and frozen in OCT compound. 
The tumors were sectioned and labeled with DAPI. Pictures in the GFP and DAPI channels for FSL and tumor cell nucleus DNA visualization were 
taken using ×4–×40 objectives (×10 example pictures are shown). The pictures show representative data of DAPI and GFP channel picture 
overlays for a vehicle‑ and a fluorescein‑lipid treated tumor from the same mouse. b In complement activation experiments, B16‑F10 tumors were 
treated by intratumoral injection of vehicle (PBS) or 1 mg AGI‑134 on Day 6 post B16‑F10 cell grafting. 2.5 h after treatment, tumors were excised, 
homogenized and the complement factor C5a measured by ELISA. Each symbol represents the total C5a in the tumor homogenate of each mouse, 
median C5a values are indicated by the bars. Differences between the PBS vs. AGI‑134 treatment groups were assessed by Mann–Whitney test 
(**p < 0.003). c In primary tumor regression experiments, back transformed least square geometric means for PBS and AGI‑134 treatments across the 
timepoints were calculated and fold‑reduction in geometric means ± 95% CI plotted, (*p < 0.05, n = 13)
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cross-presented to CD8+ T cells from CHO-OVA cells 
phagocytosed by CD8α+ murine DCs (Fig. 2c). We there-
fore hypothesized that the abscopal anti-tumor activity 
of AGI-134 in murine models of melanoma also involves 
the activation of CD8+ T cells and thus may be an excel-
lent combination partner for anti-PD-1 antibodies. To 
a B16-F10 dual flank melanoma model in  
α1,3GT-/- mice
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Fig. 4 AGI‑134 treatment of primary tumors produces an abscopal effect protecting mice from contralateral tumor development. a Schematic of 
abscopal B16‑F10 melanoma model in anti‑Gal‑expressing α1,3GT−/− mice. To monitor the abscopal effect of AGI‑134, primary B16‑F10 lesions were 
treated once by intratumoral injection of PBS or 1 mg AGI‑134 and the development of contralateral lesions monitored. The percentages of mice 
without visible/palpable contralateral tumors are plotted in the graphs. The solid arrows indicate the day of AGI‑134 or mock treatment (Day 4–6). 
b The pooled data from four independent experiments where the abscopal effect in B16‑F10 tumors was monitored over 25 days are summarized. 
c B16‑F10 tumors in immunized (anti‑Gal positive) or non‑immunized (anti‑Gal negative) α1,3GT−/− mice were treated i.t. with vehicle, or 1 mg 
AGI‑134. d Representative data from two experiments where the abscopal effect of AGI‑134 in B16‑F10 tumors was monitored over 60–90 days is 
shown. Statistical differences between treatment groups in each plot were analyzed by Mantel–Cox test (**p < 0.005; ***p < 0.0005)
Table 1 Abscopal effect of AGI-134 in in four independent experiments: incidence of distal B16-F10 tumor development 
after treatment of a primary B16-F10 tumor with AGI-134 or vehicle
Experiment # Observation period (days) Mice with 2° tumors at end of the observation period Mantel–Cox test results
AGI‑134 group PBS group
1 25 2/10 (20%) 8/10 (80%) **p = 0.0017
2 31 2/10 (20%) 8/10 (80%) *p = 0.009
3 32 0/7 (0%) 7/7 (100%) ***p = 0.0002
4 32 2/10 (20%) 10/10 (100%) ***p = 0.0004
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test this, we performed combination studies using AGI-
134 and RMP1-14, a murine specific anti-PD-1 antibody, 
in the α1,3GT−/− mouse B16-F10 melanoma model.
To evaluate the effects of combining AGI-134 and anti-
PD-1, we first identified conditions in which each com-
pound, when administered alone, had suboptimal efficacy 
in the α1,3GT−/− B16-F10 mouse model. As described 
above, administration of 0.1-mg and 0.5-mg doses of 
AGI-134 to primary tumors provided protection from 
contralateral tumor development that was significant, 
but less pronounced than 1  mg AGI-134 (Additional 
file  5: Fig. S5B). When administered in four consecu-
tive 0.25-mg intraperitoneal (i.p.) doses, starting at day 5 
post tumor cell grafting, RMP1-14 significantly protected 
mice from contralateral tumor development (Additional 
file  5: Fig. S5C). However, when RMP1-14 treatment 
was started on Day 8 or 10 post tumor cell grafting, no 
protection was conferred (data not shown). Based upon 
these observations, combination experiments were per-
formed using single doses of 0.1 or 0.25 mg of AGI-134, 
administered intratumorally on Day 5 post cell grafting, 
with four 0.25  mg i.p. doses of RMP1-14 beginning on 
Day 8 or Day 10 (Fig. 6a).
Of 17 α1,3GT−/− mice treated with the combination of 
AGI-134 and RMP1-14, only one mouse (6%) developed 
a distal tumor within the 35-day observation period, i.e., 
16 of the mice (94%) were protected (Fig. 6b). In contrast, 
77% of the mock treated animals (PBS i.t.; PBS i.p.) devel-
oped a distal tumor. Importantly, the degree of protec-
tion conferred by the AGI-134/RMP1-14 combination 
was statistically significantly greater than that seen in 
the AGI-134 or RMP1-14 only groups, in which 38% and 
62% of the animals developed distal lesions, respectively. 
Overall, these data suggest that AGI-134 has the poten-
tial to be an excellent combination partner for anti-PD-1 
antibodies by activating T cells specific to the autologous 
TSAs prior to the expansion of the activated T cell clones 
by checkpoint inhibitors.
Discussion
The natural anti-Gal antibody produces a powerful 
immune response that drives the hyperacute rejection of 
α-Gal-positive xenogeneic tissue [48, 49]. In addition to 
the hyperacute response, anti-Gal has been demonstrated 
to drive adaptive immunity to viruses that were engi-
neered to express α-Gal epitopes [22]. These properties 
have led researches to assess the ability of α-Gal-based 
immunotherapies to treat cancer through the creation 
of adaptive immunity to TSAs. Two main routes have 
been adopted to achieve this: the first involves the in situ 
labelling of tumor tissue with natural α-Gal glycolipids by 
intratumoral injection, which aims to create immunity to 
each patient’s unique TSAs [15, 16]; the second involves 
the subcutaneous administration of allogenic whole cells 
that have been modified to express α-Gal, which aims 
to create immunity to generic TSAs [14, 24–26]. Both 
approaches have significant disadvantages that have been 
addressed in the development of AGI-134.
Since most TSAs are the result of mutations that are 
specific to patient, allogeneic tumor cell lines may lack 
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Fig. 5 AGI‑134 protects mice from secondary tumor development and improves survival in a JB/RH melanoma model. Anti‑Gal‑expressing 
α1,3GT−/− mice were grafted with 5 × 105 JB/RH cells to create a 1° tumor on one flank and 2 × 104 JB/RH cells on the contralateral flank. 4–5 days 
after grafting, the 1° tumors were treated once with 1 mg AGI‑134 or PBS and contralateral tumor development (a) and mouse survival (b) 
monitored. Pooled data from three independent experiments are shown. Statistical differences between treatment groups were analyzed by 
Mantel‑Cox test (*p < 0.05). The solid arrows indicate the day of AGI‑134 or mock treatment (Day 4 or 5)
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many of the TSAs that could elicit a protective immune 
response in the individual patient [27].
Allogeneic whole cell vaccines face several issues: the 
cells contain abundant immunodominant antigens, such 
as the HLA molecules on the cells, in addition to the fact 
that vaccine relies upon the antigens within the deliv-
ered cells being both immunogenic and identical to those 
expressed by host lesions [27]. To overcome these signifi-
cant issues, an α-Gal-based immunotherapy that labels a 
patient’s tumor mass in situ, and thereby creating immu-
nity to the patient’s own set of unique TSAs is required. 
This is achieved by administering α-Gal glycolipids 
directly into a cancer lesion, which spontaneously inserts 
into the plasma membranes of the tumor cells, present-
ing the α-Gal epitope for binding with natural anti-Gal 
antibodies and driving CDC and ADCC of the tumor 
cells. Of note, AGI-134 may also drive localized direct 
killing of cancer cells as it is cytotoxic in  vitro at high 
concentrations (data not shown). Previous pre-clinical 
and clinical work utilized natural α-Gal glycolipids that 
were extracted from rabbit erythrocytes [15, 16, 28, 29]. 
However, it is technically challenging to fully character-
ize batch-to-batch composition differences of rabbit 
erythrocyte-derived glycolipids, or produce them using 
a controlled process that enables their development as a 
human therapeutic. Our data provided herein suggests 
that the fully synthetic small molecule AGI-134 has the 
immunological functionality of naturally derived α-Gal 
glycolipids, but through having a scalable, refined and 
cost-effective manufacturing route, is amenable to full 
development as a human therapeutic.
To address how anti-Gal binding to α-Gal drives 
adaptive immunity to non-self antigens in the context 
of tumors injected with α-Gal glycolipids, the array of 
effector functions elicited by the polyclonal repertoire 
of anti-Gal antibodies must be considered. Of particu-
lar importance are the anti-Gal IgM and IgG subclasses. 
Anti-Gal IgM, which comprises greater than 1% of total 
serum IgM, is a powerful complement fixer and has been 
demonstrated to be largely responsible for the comple-
ment-mediated hyperacute rejection of xenogeneic trans-
plants [50]. It is known that complement activation can 
induce lysis of cancer cells by CDC, through the depo-
sition of membrane attack complex on cell surfaces. We 
have shown that AGI-134 mediates CDC effectively in 
both SW480 and A549 human cancer cells. Interestingly, 
the latter cell line was more resistant to CDC, i.e., more 
AGI-134 was necessary to facilitate A549 cell lysis by 
human serum which may be due to higher expression of 
complement regulatory proteins such as CD55 and CD59 
[61]. In addition, complement activation has a number 
of effects that actively link innate and adaptive immu-
nity [51, 52]. When the classical complement cascade is 
activated through recognition of IgM or IgG on cells, the 
resulting cascade results in the deposition of complement 
proteins [62] that can be recognized by various APCs. For 
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Fig. 6 AGI‑134 synergizes with an anti‑PD‑1 antibody. a Schematic for testing efficacy of AGI‑134 in combination with RMP1‑14, an anti‑PD‑1 
antibody. b On Day 5 after B16‑F10 cell grafting, mice were treated i.t. with single 100 or 250 µg doses of AGI‑134 or vehicle, and then 
intraperitoneally with four 250‑μg doses of RMP1‑14 or vehicle in 3–4‑day intervals starting on Day 8 (experiment #1) or Day 10 (experiment #2) 
post B16‑F10 cell grafting. For the graph, the data from two independent experiments were combined and plotted. The data show the percentage 
of mice free from secondary tumors over time. The treatment groups were statistically compared by Mantel–Cox test (*p < 0.05; **p < 0.005; 
***p < 0.0005). Solid arrows indicate the time of i.t. AGI‑134 or vehicle treatment; dashed arrows show the start of i.p. RMP1‑14 treatment
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example, C3b/C3bi are recognized by complement recep-
tor 1 (CR1) on macrophages [18], while soluble antigens 
complexed with C3d/C3dg are bound by CR2 on follicu-
lar DCs, which present antigen to B cells during prolifera-
tion and class switching in germinal centers [53]. We have 
demonstrated here that C3b/C3bi is deposited on AGI-
134-treated cells after incubation with human serum and 
that human macrophages specifically phagocytose these 
cells. During complement activation, the anaphylatoxins 
C3a and C5a are released through proteolytic cleavage of 
precursor proteins. In particular, C5a is a powerful che-
moattractant that recruits monocytes to the site of com-
plement activation and stimulates their differentiation 
into macrophages and DCs [54]. We have demonstrated 
that AGI-134 binds anti-Gal antibodies to treated cells, 
leading to deposition of complement proteins C3b/C3bi 
and membrane attack complex and subsequent cell lysis 
after incubation in human serum in  vitro. Additionally, 
we showed that C5a was significantly more abundant in 
B16-F10 tumors after treatment with AGI-134 compared 
to tumors treated with the vehicle control, PBS. AGI-134 
therefore induces the lysis of treated tumor cells, creating 
immune-complexed cellular debris and an inflammatory 
tumor microenvironment that is optimal for the uptake 
and processing of non-self antigens, such as TSAs, by 
APCs. Of note, C5a is known to be a chemoattractant 
for neutrophils. It would be interesting to determine in 
future studies if AGI-134 treatment can lead to neutro-
phil phagocytosis and ADCC of serum opsonized cancer 
cells in vitro and to neutrophil recruitment to the tumors 
as these effector cells may have anti-tumoral activity via 
ADCC and phagocytosis.
Functional anti-tumor immunity is largely driven by 
TSA-specific CD8+ T cells. The most important APC in 
activating CD8+ T cell responses are DCs, particularly 
the CD141+ (human) and CD8α+ (murine) conventional 
DC subsets, which are particularly efficient in cross-pres-
entation of antigen to CD8+ T cells [55, 56]. DCs may 
ingest IgG-opsonized antigen via activating cell surface 
FcγRs, which promotes DC activation, maturation and 
translocation to secondary lymphoid tissue, where they 
cross-present antigen to CD8+ T cells [19, 20]. As DCs 
express both activating and inhibitory FcγRs, the ratio 
between the two receptor subtypes has an important out-
come on the response of the DC to the antigen [57]. C5a, 
which is increased in AGI-134-treated tumors, actively 
promotes an increase in the ratio of activating to inhibi-
tory FcγR on APCs, skewing the response to ingestion of 
IgG-tagged antigens towards activation of the DC, rather 
than inhibition [58]. The role of FcγR-mediated phagocy-
tosis and processing of antigens complexed with anti-Gal 
was studied using influenza virus and HIV gp120 protein. 
In these experiments the influenza virus and HIV gp120 
protein were modified to express α-Gal epitopes and then 
administered to anti-Gal expressing α1,3GT−/− mice 
[21]. When compared to non-α-Gal-labeled HIV gp120, 
the presence of α-Gal boosted the titer of anti-gp120 
antibodies by > 100-fold. Using the same animal model, 
immunization with α-Gal-labeled influenza virus con-
ferred significantly higher protection from subsequent 
challenge with a lethal influenza dose than those immu-
nized with non-α-Gal-labeled virus [22]. The increased 
protection afforded by the α-Gal labeled virus was shown 
to be conferred by increased virus antigen-specific CD4+ 
and CD8+ T cells.
We have used an in  vitro cross presentation assay 
to demonstrate that CHO cells lysed through AGI-
134-stimulated CDC and ADCC are specifically phago-
cytosed by murine CD8α+ DCs cells (MutuDCs). 
Furthermore, when OVA-expressing CHO cells were 
treated with AGI-134 and human serum before incu-
bation with MutuDCs, the immunodominant peptide 
of OVA, SIINFEKL, was cross-presented to transgenic 
CD8+ T cells. Thus, AGI-134 is able to initiate an immu-
nological cascade that results in the activation of CD8+ 
T cells with specificity for cell-associated antigens. Pre-
vious studies showed that intratumoral administration 
of rabbit erythrocyte-derived α-Gal glycolipids into B16 
melanoma lesions led to CD8+ T cell-mediated immu-
nity to MAAs as well as to OVA as a surrogate TSA, 
proving the mechanism of α-Gal glycolipid-induced 
anti-tumor immunity [15, 16]. As with rabbit eryth-
rocyte-derived α-Gal glycolipids, AGI-134 causes the 
regression of established tumors and protects mice from 
the development of un-injected secondary lesions when 
injected into a single primary lesion, demonstrating that 
AGI-134 also confers anti-tumor immunity. When taken 
together with the in vitro cross presentation data, it can 
be assumed that AGI-134-induced antitumor immunity 
is also mediated largely by CD8+ T cells.
We have further shown that AGI-134 synergizes well 
with a checkpoint inhibitor. Immunotherapies that block 
immune checkpoints have revolutionized cancer treat-
ment. PD-1 and cytotoxic T lymphocyte-associated pro-
tein 4 (CTLA-4) are negative regulators of T cells that 
promote T cell anergy in the tumor microenvironment. 
Monoclonal antibodies that target PD-1 and CTLA-4 
promote activation and expansion of T cells by blocking 
these immune checkpoints and have demonstrated effi-
cacy in a wide range of tumor types (reviewed by [59]). 
However, these treatments are only efficacious in a subset 
of patients and, particularly for anti-PD-1, activity is asso-
ciated with patients who had a T cell inflamed tumor type 
prior to starting treatment. In addition, the side effects of 
autoimmune phenomena are observed in a large propor-
tion of the patients because of activation of autoreactive 
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T cell populations. One mechanism to boost the efficacy 
of anti-PD-1 antibodies is to increase the repertoire of 
activated tumor-specific T cells prior to treatment with 
anti-PD-1. Tumors have a highly diverse array of unique 
mutations, which result in neoantigens that can be 
unique between patients, lesions and even within lesions 
[60]. However, the immunosuppressive tumor microen-
vironment often means that many of these neoantigens 
have not been effectively processed by the immune sys-
tem. As α-Gal glycolipids actively induce CD8+ T cell-
mediated immunity to TSAs and overcome regulatory T 
cell activity [16], we hypothesized that AGI-134 would 
boost the efficacy of anti-PD-1 therapy. Indeed, when we 
treated primary B16-F10 melanoma lesions in α1,3GT−/− 
mice with a combination of an anti-PD-1 treatment regi-
men that was not efficacious and a suboptimal dose of 
AGI-134, the degree of protection from secondary tumor 
development was significantly enhanced over either 
treatment when administered alone.
Conclusions
In conclusion, we have identified an α-Gal glycolipid-like 
small molecule as an immunotherapeutic drug candi-
date for the treatment of solid tumors initiated by intra-
tumoral injection. This molecule possesses the requisite 
properties that make it amenable for development as a 
human therapeutic. Anti-Gal antibodies are recruited 
to AGI-134 treated cells and stimulate CDC and ADCC 
after incubation in human serum. The CDC and ADCC-
killed cells are specifically phagocytosed by APCs and 
associated antigen cross-presented by murine CD8+ 
DCs. When injected into primary melanoma lesions in 
mice, AGI-134 protects from the development of un-
injected lesions. Finally, AGI-134 acts in synergy with an 
anti-PD-1 antibody, indicating that AGI-134 could be an 
excellent combination partner for anti-PD-1 therapy, by 
increasing the repertoire of tumor-specific T cells prior 
to anti-PD-1 treatment.
Based on the data collectively shown in this manu-
script, a first-in-man clinical study with AGI-134 has 
been initiated in July 2018 (NCT03593226). This is a 
phase I/IIa, multicenter, open-label study to evaluate 
the safety and tolerability of escalating doses of AGI-134 
given as monotherapy and in combination with pem-
brolizumab in unresectable metastatic solid tumors.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1293 5‑019‑1059‑8.
Additional file 1: Figure S1. Compound structures. (A) AGI‑
134 (functional head group is a galactose‑α‑1,3‑galactosyl‑
beta‑1,4‑N‑acetyl‑glucosamine: α‑Gal); (B) FSL‑Fluorescein 
(functional group is fluorescein); (C) FSL‑A (functional group is 
N‑acetyl‑galactosamine‑α‑1,3‑fucosyl‑α‑1,2‑galactose: blood group A 
antigen).
Additional file 2: Figure S2. Fc gamma (Fcγ) and complement recep‑
tor (CR) expression on differentiated human macrophages ((A) and (B), 
respectively). Human peripheral blood mononuclear cells were differenti‑
ated into macrophages using M‑CSF. Expression of the Fcγ receptors I–III 
(CD16, CD32, CD64) and the complement receptors CR1 (CD35), C3R 
(CD11b) and C5aR (CD88) in differentiated macrophages was verified by 
flow cytometry with fluorescently labeled surface marker specific antibod‑
ies (grey curves) and negative control isotype antibodies (open curves) 
according to standard procedures.
Additional file 3: Figure S3. Immunocytochemistry, complement 
deposition, and phagocytosis control experiments. (A) Anti‑Gal binding 
to AGI‑134 labeled B16‑F10 cells. 1 × 106 B16‑F10 cells were incubated 
with 0 or 0.5 mg AGI‑134 in PBS. Subsequently, the cells were incubated 
with a monoclonal anti‑Gal antibody. Anti‑Gal binding was visualized 
by fluorescence microscopy with FITC‑labeled secondary antibody; 
cell nuclei were stained with DAPI. (B) A549 cells were labeled with the 
indicated amounts of AGI‑134 and then incubated with 0 or 50% normal 
human serum (NHS). Deposition of the complement components C3b 
and C5b‑C9 (MAC) was detected with fluorescein‑labeled anti‑C3b or 
anti‑MAC antibodies. FL‑1 histogram overlays for a representative experi‑
ment of several performed are shown. (C) In phagocytosis experiments 
with the phagocytosis inhibitor cytochalasin D, Far Red CellTrace labeled 
human macrophages and CFSE‑labeled A549 target cells were incubated 
with AGI‑134 and NHS in the presence or absence of 5 μM cytochalasin D. 
Then, the cells were treated with trypsin/EDTA to dissociate A549 from the 
macrophages. The samples were analyzed by flow cytometry as above. 
Double positive events in the samples treated with trypsin/EDTA. Data 
shown is representative of two independent experiments: mean + SD 
of duplicate samples. (D) A549 and SW480 cells were stained with CD59, 
CD55 or control antibodies and analyzed by flow cytometry. Mean fold 
increase data shown is representative of two independent experiments: 
mean + SD.
Additional file 4: Figure S4. Binding of mouse anti‑Gal antibodies and 
complement deposition on AGI‑134‑treated mouse melanoma cells. 
(A–D) B16‑F10 or JB/RH cells were treated with the indicated AGI‑134 con‑
centrations or the negative control glycolipid FSL‑A. The cells were then 
incubated with mouse anti‑Gal IgM, serum from non‑immunized (low 
anti‑Gal titers) or PKH‑immunized (high anti‑Gal titers) α1,3GT−/− mice, or 
anti‑blood group A,B primary antibodies or buffer only. Anti‑Gal antibody 
binding or deposition of the complement factors C3b/i and C5b‑9 were 
detected using antibodies and flow cytometry. Histogram overlays for the 
various samples are plotted for representative data from several experi‑
ments performed. Of note, the samples for anti‑FSL‑A and complement 
deposition in (D) were run in parallel in the same experiment.
Additional file 5: Figure S5. (A) Anti‑Gal IgG and IgM titer in PKH‑
immunized vs. non‑immunized α1,3GT−/− mice. Five α1,3GT−/− mice 
were immunized five times with PKH. Heparinized blood before the 
first and after the last immunization was collected for each animal and 
plasma prepared. The anti‑Gal IgG and IgM titers for pre‑immune and 
post‑immunization plasma were determined by ELISA with immobilized 
α‑Gal (see methods section). The absorbance values at 492 nm  (A492) as 
read‑out for anti‑Gal binding are plotted relative to the plasma dilutions. 
(B) Representative data from experiments where the dose‑dependency 
of the abscopal effect of AGI‑134 in B16‑F10 tumors in α1,3GT−/− mice 
was monitored over 25 days are shown. (C) Abscopal effect of activity of 
four doses of intraperitoneally (i.p.) injected anti‑PD‑1 antibody RMP1‑14 
in B16‑F10 model as compared to mock treatment (Treatment start: Day 
5). (B, C) Differences in secondary tumor development over time between 
the treatment groups were calculated by Mantel‑Cox test (*, p < 0.05; ***, 
p < 0.0005).
Abbreviations
7‑AAD: 7‑aminoactinomycin D; ADCC: antibody‑dependent cellular cytotoxic‑
ity; α‑Gal: galactose‑α‑1,3‑galactosyl‑beta‑1,4‑N‑acetyl‑glucosamine; anti‑Gal: 
anti‑α‑Gal antibody; APC: antigen‑presenting cell; BSA: bovine serum albumin; 
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CDC: complement‑dependent cytotoxicity; CDS: cell dissociation solution; 
CFSE: carboxyfluorescein succinimidyl ester; CHO‑OVA: ovalbumin express‑
ing CHO‑K1 cells; CTLA‑4: cytotoxic T‑lymphocyte‑associated protein 4; 
CytD: cytochalasin D; DAPI: 4′,6‑diamidino‑2‑phenylindole; DC: dendritic cell; 
EtOH: ethanol; FBS: fetal bovine serum; FcγRIIIa: Fc gamma receptor 3a; FITC: 
fluorescein isothiocyanate; FSL: Kode Biotech function‑spacer‑lipid construct; 
GFP: green fluorescent protein; gMFI: geometric mean fluorescence intensity; 
GT: α‑1,3‑galactosyl transferase; GT KO or α1,3GT−/− mice: α‑1,3‑galactosyl 
transferase knock out mice; HSA: human serum albumin; IACUC : Institutional 
Animal Care and Use Committee; i.p.: intraperitoneal; i.t.: intratumoral; iNHS: 
heat‑inactivated normal human serum; MAA: melanoma associated antigen; 
MAC: membrane attack complex; MDM: monocyte‑derived macrophages; 
MutuDC: murine tumor dendritic cells; NHS: normal human serum; NHSBT: 
National Health Service Blood and Transplant; OT‑1: OVA‑T cell receptor‑1; OVA: 
ovalbumin; PBS: phosphate buffered saline; PD‑1: programmed cell death 1 
receptor; PDL‑1: programmed death‑ligand; PKH: pig kidney homogenate; 1°: 
primary; Rag1: recombination activating gene 1; RLU: relative light units; RRBC: 
rabbit red blood cell; RLU: relative light units; 2°: secondary; s.c.: subcutaneous; 
TSA: tumor‑specific antigen.
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